Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S ADR (NY: NVO )

105.46 +2.83 (+2.76%)
Streaming Delayed Price Updated: 11:56 AM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S ADR

< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
65 66 Next >
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
7 Weight Loss Drug Stocks Poised for Explosive Growth by 2025
The second wave of the weight loss drug stock boom is underway and investors should heed the signs the market is serving. 
Via InvestorPlace
3 Million Reasons Novo Nordisk Still Looks Like a Phenomenal Buy
This is a stock you shouldn't hesitate to buy on the dip. 
Via The Motley Fool
Biotech Breakthroughs: 7 Stocks Driving the Next Wave in Healthcare
Investors concerned about broader market undulations may want to consider the resilience narrative of these biotech stocks to buy. 
Via InvestorPlace
Investors should take note of NYSE:NVO, a growth stock that remains attractively priced.
NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) is showing decent growth, but is still valued reasonably. 
Via Chartmill
Analyzing NYSE:NVO's Dividend Potential.
Why NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) provides a good dividend, while having solid fundamentals. 
Via Chartmill
Decoding Novo Nordisk's Options Activity: What's the Big Picture?
Via Benzinga
Eli Lilly Gains on the GLP-1 Weight Loss Phenomenon
Eli Lilly stock continues to move higher after the company reported continuing momentum for its flagship GLP-1 weight loss drugs 
Via MarketBeat
'Ozempic Ftw:' Elon Musk Touts Novo Nordisk's Blockbuster Drug As Solution To Childhood Obesity Problem
This is not the first time the tech mogul has seemingly backed the blockbuster drug. Last year, Musk claimed that Ozempic was affecting food sales at Walmart. 
Via Benzinga
Eli Lilly Raised Its Outlook. Is the Stock a Buy Now?
The anti-obesity medication stock is way up, and there could be more fuel in the tank. 
Via The Motley Fool
Why Amgen Stock Zoomed Nearly 12% Higher Today
The company delivered solid quarterly results, but its discussion of an investigational drug is what really gave its shares a pop. 
Via The Motley Fool
3 Under-The-Radar Stocks That Could Be Worth Over $1 Trillion by 2030
These under-the-radar stocks have the potential to reach a $1 trillion valuation by 2030 as they gain momentum in their respective industries. 
Via InvestorPlace
Stock Market Rallies On Fed, Jobs Report, Apple: Weekly Review
The Nasdaq regained its 50-day line Friday. The other indexes hit resistance. 
Via Investor's Business Daily
Topics Economy
Exposures Interest Rates
Wage Growth Slows – Stock Market Celebrates, Five Real Reasons Apple Is Running Up
To gain an edge, this is what you need to know today. 
Via Benzinga
AMGN Stock Alert: Is Amgen the Next Hot Weight-Loss Drug Company?
Amgen (AMGN) stock is soaring after the company's CEO said he was "very encouraged" by interim data for Amgen's new weight-loss drug. 
Via InvestorPlace
The Big Split: 3 Stock Spinoffs Are Coming. Should You Buy?
Stock spinoffs can unlock shareholder value but management sometimes uses them to get rid of unwanted, slow-growing businesses. 
Via InvestorPlace
This Is a Huge Sigh of Relief for Novo Nordisk Investors
The path is clear for even more growth from Novo Nordisk's top two drugs, Ozempic and Wegovy. 
Via The Motley Fool
Weigh Loss Competition Heats Up In Britain, Online Pharmacies Slash Prices for Wegovy and Mounjaro
Reduced prices on Wegovy and Mounjaro at British pharmacies amid growing competition. Simple Online Pharmacy slashes Mounjaro starter doses to £149 from £179, catering to high demand. 
Via Benzinga
Novo Nordisk (NVO) Q1 2024 Earnings Call Transcript
NVO earnings call for the period ending March 31, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
NVO Stock Earnings: Novo Nordisk Beats EPS, Beats Revenue for Q1 2024
NVO stock results show that Novo Nordisk beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Novo Nordisk Dips As Q1 Wegovy Sales Double, But Miss Target
Novo Nordisk stock came under mild selling pressure early Thursday, after the company reported Q1 results and lifted guidance. 
Via Investor's Business Daily
Demand Soars For Novo Nordisk's Weight-Loss Drug Wegovy Despite Supply Constraints And Eli Lilly Competition
The Danish pharmaceutical company is now shipping more introductory doses of Wegovy to the U.S., as it grapples with supply constraints and competition from Eli Lilly. 
Via Benzinga
Federal Trade Commission Targets 'Junk Patent Listings' For Diabetes, Weight Loss, Asthma Drugs From Companies Like Novo Nordisk, AstraZeneca
The FTC intensifies efforts against pharmaceutical patent listings, disputing junk patents for diabetes, weight loss, asthma, and COPD medications. This initiative combats tactics hindering generic... 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Profit from the Panic: 3 Stocks to Pounce on When They Become Steals
We love it when our favorite clothes go on sale, so when the market offers us a deal, these are the stocks to buy on dips. 
Via InvestorPlace
Moody’s, Booking, DraftKings, Amgen Stocks In Focus Ahead Of Earnings
American stocks were mixed on Wednesday as the earnings season continued and as investors waited for the latest Federal Reserve decision. The Dow Jones rose by over 65 points while the S&P 500 and... 
Via Talk Markets
Topics Economy Stocks
Exposures Interest Rates US Equities
Stock Market Crash Warning: Don’t Get Caught Holding These 3 Consumer Stocks.
While some retail companies are still thriving, investors would be smart to steer clear of these consumer stocks to avoid. 
Via InvestorPlace
Setback For Novo Nordisk? Denmark Shifts Prescription Guidelines, Favoring Cost-Effective Alternatives For Ozempic
The agency noted that in 2023, half of the new type 2 diabetes patients started their treatment with a reimbursed GLP-1 drug without trying a cheaper alternative first. 
Via Benzinga
How Consumer Demand Is Impacting Taiwan Semiconductor Manufacturing Co.
We also look at the "treasure hunt" economy. 
Via The Motley Fool
3 of Europe’s ‘Magnificent 18’ Stocks That You Can Buy in the U.S.
The Magnificent Seven is so yesterday. The new trend is to invest in some of the top European stocks, dubbed the Magnificent 18. 
Via InvestorPlace
Eli Lilly Stock Jumps On Strong Earnings, Guidance As Zepbound Sales Easily Beat
Overall revenue fell short in Q1. Lilly stock is set to cross a key level. 
Via Investor's Business Daily
< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
65 66 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.